Weight maintenance studies suggest ongoing dosing is required
The introduction of piretanide in the 1980s also did not consistently affect glucose tolerance or insulin levels, though both piretanide and furosemide were linked to changes in cholesterol levels in hypertensive patients (Valimaki et al., 1983
NASH can progress to fibrosis, cirrhosis, and in some cases, particularly those with advanced fibrosis or cirrhosis, to hepatocellular carcinoma
Semaglutide is a human GLP-1 analog that has been shown to significantly improve glycemic control and reduce body weight, in addition to improving cardiovascular outcomes, in patients with T2D
If you meet any of the following criteria, you may not be eligible for a prescription of GLP-1 weight loss medication: 1
These risks can vary depending on your overall health, existing medical conditions, and the doses of each medication